MaxCyte financials
$1.18+1.72%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $33.0M | $38.6M | $41.3M | $44.3M | $33.9M |
| Gross profit | $26.8M | $31.5M | $36.5M | $39.2M | $30.2M |
| Gross margin | 81.2% | 81.6% | 88.5% | 88.5% | 89.2% |
| Operating income | -$51.9M | -$51.2M | -$48.3M | -$27.4M | -$18.2M |
| Net income | -$44.6M | -$41.1M | -$37.9M | -$23.6M | -$19.1M |
| Net margin | −135.1% | −106.3% | −91.8% | −53.3% | −56.3% |
| Diluted EPS | $-0.42 | $-0.39 | $-0.37 | $-0.23 | $-0.21 |
| EBITDA | -$40.9M | -$46.9M | -$44.1M | -$23.9M | -$16.8M |
| Operating cash flow | -$34.4M | -$27.6M | -$21.7M | -$14.8M | -$10.7M |
| Free cash flow | -$36.2M | -$29.3M | -$25.4M | -$33.3M | -$14.5M |
| Diluted shares | 106.4M | 104.8M | 103.3M | 101.7M | 90.6M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $20.1M | $27.9M | $46.5M | $11.1M | $47.8M |
| Short-term investments | $83.0M | $126.6M | $121.8M | $216.3M | $207.3M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $202.5M | $239.5M | $268.3M | $286.7M | $284.1M |
| Total liabilities | $31.0M | $33.2M | $36.1M | $32.7M | $21.2M |
| Shareholders' equity | $171.5M | $206.3M | $232.2M | $254.0M | $262.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology